We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Y mAbs Therapeutics Inc | NASDAQ:YMAB | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.10 | -0.58% | 17.15 | 15.60 | 18.93 | 17.7775 | 16.987 | 17.50 | 246,023 | 01:00:00 |
From May 2021 to May 2024
By Chris Wack
Y-mAbs Therapeutics Inc. shares were up 28% to $8.38 Friday after the company said it recently completed a pre-biologics license application meeting with the U.S. Food and Drug Administration regarding a potential pathway for FDA approval of omburtamab for the treatment of patients with CNS/leptomeningeal metastases from neuroblastoma.
The stock hit its 52-week low of $6.50 on Thursday, and finished that session down 7%.
The biopharmaceutical company said it expects to resubmit the biologics license application for omburtamab by the end of the first quarter 2022.
A data readout from a single-center clinical study showed that patients had a median survival of 50 months, with the final median not yet being reached. The company said it intends to submit the complete clinical data package in the BLA and announce the data later this year.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 11, 2022 12:47 ET (17:47 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Y mAbs Therapeutics Chart |
1 Month Y mAbs Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
